About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 294389, 6 pages
http://dx.doi.org/10.1155/2010/294389
Review Article

Cytokines and Their STATs in Cutaneous and Visceral Leishmaniasis

1Department of Microbiology, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA
2Center for Microbial Interface Biology, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA

Received 9 September 2009; Accepted 18 November 2009

Academic Editor: Luis I. Terrazas

Copyright © 2010 Hannah E. Cummings et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The Center for Disease Control, “Parasites and health: leishmaniasis,” 2008, http://www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm.
  2. B. L. Herwaldt, “Leishmaniasis,” The Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. F. J. Tapia, G. Cáceres-Dittmar, and M. A. Sánchez, Molecular and Immune Mechanisms in the Pathogenesis of Cutaneous Leishmaniasis, R. G. Landes, Austin, Tex, USA, 1996.
  4. D. Sacks and A. Sher, “Evasion of innate immunity by parasitic protozoa,” Nature Immunology, vol. 3, no. 11, pp. 1041–1047, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. E. Rosas, T. Keiser, J. Barbi, et al., “Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice,” International Immunology, vol. 17, no. 10, pp. 1347–1357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Alexander, A. R. Satoskar, and D. G. Russell, “Leishmania species: models of intracellular parasitism,” Journal of Cell Science, vol. 112, no. 18, pp. 2993–3002, 1999. View at Scopus
  7. S. Stäger, J. Alexander, K. C. Carter, F. Brombacher, and P. M. Kaye, “Both interleukin-4 (IL-4) and IL-4 receptor α signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity,” Infection and Immunity, vol. 71, no. 8, pp. 4804–4807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Alexander, K. Christine Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher, “Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis,” European Journal of Immunology, vol. 30, no. 10, pp. 2935–2943, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Tripathi, V. Singh, and S. Naik, “Immune response to leishmania: paradox rather than paradigm,” FEMS Immunology and Medical Microbiology, vol. 51, no. 2, pp. 229–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leishmania: paradox rather than paradigm,” Immunology Letters, vol. 99, no. 1, pp. 17–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. G. Reed, “TGF-β in infections and infectious diseases,” Microbes and Infection, vol. 1, no. 15, pp. 1313–1325, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Kroof, S. Herath, V. Weber, M. Modolell, and I. Müller, “Factors influencing Leishmania major infection in IL-4-deficint BALB/c mice,” Parasite Immunology, vol. 25, no. 8-9, pp. 439–447, 2003.
  14. L. R. Castellano, D. C. Filho, L. Argiro, et al., “Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-γ production,” Human Immunology, vol. 70, no. 6, pp. 383–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. U. Buxbaum and P. Scott, “Interleukin 10- and Fcγ receptor-deficient mice resolve Leishmania mexicana lesions,” Infection and Immunity, vol. 73, no. 4, pp. 2101–2108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. B. N. Thomas and L. U. Buxbaum, “FcγRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions,” Infection and Immunity, vol. 76, no. 2, pp. 623–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Wurster, T. Tanaka, and M. J. Grusby, “The biology of Stat4 and Stat6,” Oncogene, vol. 19, no. 21, pp. 2577–2584, 2000. View at Scopus
  18. N. G. Jacobson, S. J. Szabo, R. M. Weber-Nordt, et al., “Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4,” Journal of Experimental Medicine, vol. 181, no. 5, pp. 1755–1762, 1995. View at Scopus
  19. L. E. Rosas, H. M. Snider, J. Barbi, et al., “Cutting edge: STAT1 and T-bet play distinct roles in determining outcome of visceral leishmaniasis caused by Leishmania donovani,” Journal of Immunology, vol. 177, no. 1, pp. 22–25, 2006. View at Scopus
  20. J. Bromberg and J. E. Darnell Jr., “The role of STATs in transcriptional control and their impact on cellular function,” Oncogene, vol. 19, no. 21, pp. 2468–2473, 2000. View at Scopus
  21. D. J. Ghosh, D. E. Levy, R. W. Johnstone, and C. J. Clarke, “IFNγ signaling- does it mean JAK-STAT?” Cytokine & Growth Factor Reviews, vol. 19, no. 5-6, pp. 282–394, 2008.
  22. D. M. Mosser and J. P. Edwards, “Exploring the full spectrum of macrophage activation,” Nature Reviews Immunology, vol. 8, no. 12, pp. 958–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Imada and W. J. Leonard, “The Jak-STAT pathway,” Molecular Immunology, vol. 37, no. 1-2, pp. 1–11, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. L. E. Rosas, T. Keiser, R. Pyles, J. Durbin, and A. R. Satoskar, “Development of protective immunity against cutaneous leishmaniasis is dependent of STAT1-mediated IFN signaling pathway,” European Journal of Immunology, vol. 33, no. 7, pp. 1799–1805, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Bowen, A. Kelly, T. Lee, and P. Lavender, “Control of cytokine gene transcription in Th1 and Th2 cells,” Clinical and Experimental Allergy, vol. 38, no. 9, pp. 1422–1431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Barbi, H. M. Snider, N. Bhardwaj, C.M. Lezama-Dávila, J. E. Durbin, and A. R. Satoskar, “Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection,” The FASEB Journal, vol. 23, no. 11, pp. 3990–3999, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Barbi, S. Oghumu, C. M. Lezama-Davila, and A. R. Satoskar, “IFN-γ and STAT1 are required for efficient induction of CXC chemokine receptor 3 (CXCR3) on CD4+ but not CD8+ T cells,” Blood, vol. 110, no. 6, pp. 2215–2216, 2007.
  28. L. E. Rosas, J. Barbi, B. Lu, et al., “CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection,” European Journal of Immunology, vol. 35, no. 2, pp. 515–523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Johnson and P. Scott, “STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major,” Journal of Immunology, vol. 178, no. 11, pp. 7259–7266, 2007. View at Scopus
  30. A. Diefenbach, H. Schindler, N. Donhauser, et al., “Type I interferons (IFNα/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite,” Immunity, vol. 8, no. 1, pp. 77–87, 1998.
  31. L. Xin, K. Li, and L. Soong, “Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes,” Molecular Immunology, vol. 45, no. 12, pp. 3371–3382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. W. T. Watford, B. D. Hissong, J. H. Bream, Y. Kanno, L. Muul, and J. J. O'Shea, “Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4,” Immunological Reviews, vol. 202, pp. 139–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. McDowell and D. L. Sacks, “Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses,” Current Opinion in Microbiology, vol. 2, no. 4, pp. 438–443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. A. R. Satoskar, S. Rodig, S. R. Telford III, et al., “IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology,” European Journal of Immunology, vol. 30, no. 3, pp. 834–839, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Rodriguez-Sosa, G. M. Monteforte, and A. R. Satoskar, “Susceptibility to Leishmania mexicana infection is due to the inability to produce IL-12 rather than lack of IL-12 responsiveness,” Immunology and Cell Biology, vol. 79, no. 4, pp. 320–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Nelms, H. Huang, J. Ryan, A. Keegan, and W. E. Paul, “The IL-4 receptor: signaling mechanisms and biological functions,” Advances in Experimental Medicine and Biology, vol. 452, pp. 37–43, 1998. View at Scopus
  38. D. Hebenstreit, G. Wirnsberger, J. Horejs-Hoeck, and A. Duschl, “Signaling mechanisms, interaction partners, and target genes of STAT6,” Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 173–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Satoskar, H. Bluethmann, and J. Alexander, “Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection,” Infection and Immunity, vol. 63, no. 12, pp. 4894–4899, 1995. View at Scopus
  40. C. R. Engwerda, S. C. Smelt, and P. M. Kaye, “An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice,” Experimental Parasitology, vol. 84, no. 2, pp. 195–202, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. M. E. Wilson, B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan, “The importance of TGF-β in murine Visceral leishmaniasis,” Journal of Immunology, vol. 161, no. 11, pp. 6148–6155, 1998. View at Scopus
  42. S. Stäger, J. Alexander, A. C. Kirby, et al., “Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses,” Nature Medicine, vol. 9, no. 10, pp. 1287–1292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. L. U. Buxbaum, “A detrimental role for IgG and FcgammaR in Leishmania mexicana infection,” Immunologic Research, vol. 42, no. 1-3, pp. 197–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Bhowmick, T. Mazumdar, and N. Ali, “Vaccination route that induces transforming growth factor β production fails to elicit protective immunity against Leishmania donovani infection,” Infection and Immunity, vol. 77, no. 4, pp. 1514–1523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. L. Murphy, U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell, “IL-10 mediates susceptibility to Leishmania donovani infection,” European Journal of Immunology, vol. 31, no. 10, pp. 2848–2856, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. H. W. Ghalib, M. R. Piuvezam, Y. A. W. Skeiky, et al., “Interleukin 10 production correlates with pathology in human Leishmania donovani infections,” Journal of Clinical Investigation, vol. 92, no. 1, pp. 324–329, 1993. View at Scopus
  47. D. Nandan and N. E. Reiner, “Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1,” Clinical Immunology, vol. 114, no. 3, pp. 266–277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. D. M. Mosser and X. Zhang, “Interleukin-10: new perspectives on an old cytokine,” Immunological Reviews, vol. 226, no. 1, pp. 205–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Takeda, T. Tsuneyasuk, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira, “Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T-cell- specific stat3-deficient mice,” Journal of Immunology, vol. 161, no. 9, pp. 4652–4660, 1998. View at Scopus
  50. K. Takeda, B. E. Clausen, T. Kaisho, et al., “Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils,” Immunity, vol. 10, no. 1, pp. 39–49, 1999. View at Publisher · View at Google Scholar · View at Scopus